We are happy to welcome John Gustofson to our Board of Directors
Hyku Biosciences
生物技术研究
Lexington，Massachusetts 1,082 位关注者
Expanding the Boundaries of Covalent Therapies
关于我们
With a singular goal to improve patient lives, Hyku is pioneering precise covalent targeting of disease-causing proteins and transforming conventional treatment paradigms
- 网站
-
https://www.hykubiosciences.com/
Hyku Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Lexington，Massachusetts
- 类型
- 私人持股
地点
-
主要
获取路线
1050 Waltham St
US，Massachusetts，Lexington，02421
Hyku Biosciences员工
动态
-
We are excited to announce that Dr. Andrea Zuhl, Hyku’s VP, Chemical Biology and Proteomics, will be presenting at the 2024 Discovery on Target meeting in Boston on September 30th. Her talk, entitled “Specific Covalent Targeting of Histidine, Tyrosine, and Lysine to Expand the Druggable Proteome”, will focus on key features of Hyku’s platform that enable development of novel, covalent and non-covalent therapeutics for unmet patient needs.
Covalent Chemistries and Induced Proximity | Discovery On Target | Sept 30 - Oct 3, 2024
discoveryontarget.com
-
Hyku Biosciences is pleased to announce that Dr. Kleem Chaudhary has come on board as our new President and CEO! We are excited for Kleem to lead us into the future as we develop novel therapeutics that address serious unmet needs of patients. https://lnkd.in/ezgbfWew
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth
globenewswire.com